Filing scope and business context
Filing identity: The supplied filing is Therapix Biosciences Ltd.’s Form 20-F for the fiscal year ended December 31, 2017, filed April 30, 2018. This differs from the request metadata, which identifies Scisparc Ltd. and “2017 Q4”; the filing is an annual report for Therapix, not a quarterly report. Financial statements are audited under IFRS and presented in U.S. dollars, while the company’s functional currency is the Israeli shekel.
Therapix was a clinical-stage cannabinoid-drug developer with no product sales. Its main programs repurposed dronabinol: THX-110 for Tourette syndrome (and development work in pain and obstructive sleep apnea) and THX-130 for mild cognitive impairment. It intended to pursue the FDA’s Section 505(b)(2) pathway. The company reported 139,885,534 ordinary shares outstanding at year-end; each ADS represents 40 ordinary shares.
Financial performance and position
Amounts below are in USD millions unless otherwise noted. The filing reports no revenue from product sales; therefore, revenue-based margins are not meaningful.
| Metric | 2017 | 2016 | Change or context |
|---|---|---|---|
| Revenue | None | None | No product revenue since inception |
| Research and development expense | $1.943 | $0.740 | Up 163%, mainly clinical studies and formulation work |
| General and administrative expense | $3.810 | $1.268 | Up substantially; higher compensation, professional fees, investor relations and business expenses |
| Operating loss | $5.754 | $2.000 | Loss widened |
| Net loss | $6.244 | $2.007 | Loss widened; 2017 included $0.490 net finance expense, mainly foreign-exchange losses |
| Basic and diluted loss per ordinary share | $0.05 | $0.05 | ADS loss per share was reported as $2.14 in both years |
| Net cash used in operating activities | $4.579 | $1.474 | Higher operating cash burn |
| Cash and cash equivalents | $9.195 | $0.676 | Excludes $0.024 restricted cash at year-end 2017 |
| Total assets | $9.566 | $1.245 | |
| Total liabilities | $1.177 | $0.672 | Primarily trade and other payables; no borrowings are identified in the presented balance sheet |
| Total equity | $8.389 | $0.573 | |
| Accumulated deficit | $38.389 | $32.145 |
Financing cash flow was $13.175 million in 2017, principally reflecting equity and warrant-related proceeds; investing cash outflow was $0.053 million. The March 2017 U.S. IPO generated approximately $12.0 million net proceeds. By year-end, the company reported using about $1.7 million for R&D and $3.4 million for business development, G&A and working capital.
Management expected year-end cash resources to fund current operations at least through June 30, 2019, but said substantial additional capital would be needed for continued development and commercialization. The filing also states cash was expected to cover at least 18 months from the April 24, 2018 financial-statement approval date. The company had no off-balance-sheet arrangements. It disclosed contractual commitments including approximately $1.458 million for license and development agreements; a separate lease note describes approximately $0.186 million of remaining minimum payments.
Material changes versus prior periods
- R&D spending rose as cannabinoid programs advanced into clinical work; the company reported $0.511 million of clinical-study expense in 2017, versus none in 2016.
- G&A expense increased to $3.810 million from $1.268 million. The filing’s narrative mistakenly calls this a “decrease” in one passage, although the reported amounts show a substantial increase.
- Operating cash use rose to $4.579 million from $1.474 million. The cash balance increased primarily through 2017 financing, not operating performance.
- Ordinary shares outstanding increased from 40,998,471 at year-end 2016 to 139,885,534 at year-end 2017, reflecting financing and share issuances.
- The company changed its financial-statement presentation currency to U.S. dollars; its functional currency remained NIS. Foreign-exchange effects contributed materially to 2017 finance expense.
Outlook, risks, contingencies and unusual items
- Clinical and regulatory outlook: In April 2018, after the reporting year, the company announced topline results from a 16-subject, open-label Phase IIa THX-110 study: average tic-score reduction was 21%, and 6 of 16 participants had a reduction greater than 25%. The study was small and uncontrolled; the filing says no significant effects were observed on listed comorbid symptoms. Management planned a randomized, placebo-controlled Phase IIb study of about 60 patients in Europe, targeted to start in Q3 2018. These are plans, not completed milestones.
- THX-130: The company planned a Phase I study to assess safety and pharmacokinetics, alongside additional preclinical work. Its supporting cognitive findings were preclinical; human efficacy had not been established.
- Funding and dilution: The company had recurring losses, no operating revenue and dependence on future external financing. Financing may be unavailable or dilutive and could force program delays or curtailment. Management warned that funding shortfalls could raise substantial doubt about continuing operations.
- Regulatory and product risks: No candidate had marketing approval or had entered pivotal trials. The anticipated 505(b)(2) route was uncertain and could require more studies. Dronabinol was described as a Schedule I controlled substance, requiring rescheduling before U.S. commercial marketing after any FDA approval. Potential cannabinoid-related adverse effects, trial failure, enrollment, manufacturing and third-party CRO risks were highlighted.
- Orphan designation: The FDA had not granted THX-110 orphan-drug designation and requested additional prevalence information. Therapix submitted further information in January 2018 and was awaiting a response.
- Related-party license: The Dekel license is with a company controlled by Chairman and interim CEO Ascher Shmulewitz. A 2017 amendment would convert potential royalties, milestones and other financial consideration into 19 million ordinary shares if a financing of at least $5 million closed by June 30, 2018 and specified approvals were obtained. The filing identifies a potential conflict of interest.
- Legal and other contingencies: In 2017 the company settled an Israeli Securities Authority inquiry, admitted disclosure-related breaches and agreed to a monetary sanction of NIS 150,000; the chairman also faced a probationary condition. The filing describes possible further sanctions for repeat breaches and a related investor-compensation provision. Past Israeli Innovation Authority grants may entail royalties and restrictions on transfer of funded know-how. The attempted transfer of Anti-CD3 rights encountered approval issues and was subject to a later mutual termination and IIA approval process.
- Governance and controls: Management reported effective disclosure controls and internal control over financial reporting at December 31, 2017. The independent auditor issued an unqualified IFRS opinion, but did not attest to internal-control effectiveness; the company cited its emerging-growth-company exemption.
- Other investor risks: The filing notes exchange-rate exposure, volatile and potentially limited ADS trading, competition, patent and licensing uncertainty, Israeli geopolitical and operating risks, no expected dividends, and possible PFIC status for U.S. tax purposes.
Important facts for investors to verify
- Confirm issuer and period: the source is Therapix Biosciences Ltd.’s FY2017 Form 20-F, not a Scisparc Ltd. filing or a quarterly report.
- Review the audited financial statements and cash-flow assumptions, including the basis for the stated June 2019 runway and the pace of subsequent cash burn.
- Check the status and results of the planned THX-110 Phase IIb trial, the FDA orphan-designation request, and THX-130’s clinical entry; distinguish company plans and preclinical evidence from established clinical efficacy.
- Verify the Dekel amendment’s financing and approval conditions, the potential 19 million-share issuance, related-party safeguards and any subsequent developments.
- Reconcile the filing’s different descriptions of 2017 G&A change, comprehensive loss, and lease commitments; check the underlying statements and notes where figures appear inconsistent.
- Assess potential dilution from outstanding options and future capital raising, and review the ISA sanction, repeat-violation terms and related indemnification exposure.